Sanofi’s Principia purchase fails its first test
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.
Tori’s lung cancer hit raises a key question
The Junshi/Coherus drug only beat chemotherapy, and its study was run not in the US but in China.
Arcus nears crunch time for Gilead opt-in
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
Bristol’s buy moves it to the top of the sales charts
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
Dangling PD-1s emerge strong from three-day grilling
A US advisory panel has largely endorsed three anti-PD-(L)1 drugs, with voting apparently driven by the availability of alternatives.
Three days of reckoning for checkpoint blockers
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
